Skip to content

Clinical study of regulating immune cells by Yiqi Huayu Jiedu method to reduce the risk of recurrence and metastasis after operation of stage II and III colorectal cancer -- retrospective study

Clinical study on regulating immune cells by Yiqi Huayu Jiedu to reduce the risk of recurrence and metastasis of stage II and III colorectal cancer after operation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000943
Enrollment
Unknown
Registered
2025-05-10
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Exposed group:Chemotherapy + Traditional Chinese Medicine

Sponsors

Department of Oncology Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for colorectal cancer and have undergone radical surgery; (2) XELOX or FOLFOX or FOLFIRI was the main regimen of postoperative adjuvant chemotherapy; (3) Such as oral Chinese medicine prescriptions mainly to Yiqi Huayu detoxification method; (4) 18 years old =90 years old; (5) Clearly aware of being able to complete the questionnaire independently or with the help of family members; (6) Agree to participate in this research.

Exclusion criteria

Exclusion criteria: (1) Patients diagnosed with metastatic colorectal cancer at first diagnosis whose local recurrence or distant metastasis has been confirmed by histopathology or imaging examination; (2) Malignant tumors in other parts of the body including high-grade intraepithelial neoplasia and severe dysplasia in esophagus stomach and cervix; (3) Patients undergoing palliative surgery; (4) Gender age operation time postoperative pathological results and other data in the data are incomplete and irreparable resulting in the inability to judge the stage recurrence and metastasis time; (5) There are cognitive and communication barriers unable to cooperate with the investigation; (6) Complicated with serious primary heart liver lung kidney blood or serious diseases affecting their survival.

Design outcomes

Primary

MeasureTime frame
1-year and 2-year progression-free survival rates;DFS;

Countries

China

Contacts

Public ContactZhuang Yuwen

Jiangsu Province Hospital of Chinese Medicine

zhuangyuwen21@126.com18512526403

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026